Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + tramadol
- Development stage
- Unknown
- Lead developer
- Kims Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KIMS-003 is an incrementally modified drug (IMD) being developed by Kims Pharmaceutical for the management of pain. It is a fixed-dose combination (FDC) comprising the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib and the atypical opioid analgesic tramadol. The combination is designed to provide enhanced pain relief by targeting multiple pathways: celecoxib reduces prostaglandin synthesis to alleviate inflammation and peripheral pain, while tramadol acts centrally as a mu-opioid receptor agonist and a serotonin-norepinephrine reuptake inhibitor (SNRI). This multimodal approach aims to improve efficacy and potentially reduce the required doses of individual components, thereby minimizing side effects. KIMS-003 is currently undergoing Phase 1 clinical trials in South Korea to evaluate its pharmacokinetic profile and safety compared to the co-administration of its individual components.
- Other names
- KIMS003KIMS-003KIMS 003
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on celecoxib + tramadol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + tramadol.